Table 2 Description of patients by treatment arm and clinical setting
| Â | Whole set | Locally advanced | Metastatic not pre-treated with anthracyclines | Metastatic pre-treated with anthracyclines | ||||
|---|---|---|---|---|---|---|---|---|
| Â | 3-weekly N = 69 | Weekly N = 66 | 3-weekly N = 22 | Weekly N = 20 | 3-weekly N = 26 | Weekly N = 26 | 3-weekly N = 21 | Weekly N = 20 |
Age, median (range), yrs | 52 (33-68) | 50 (30-69) | 48 (33-65) | 45 (30-66) | 54 (34-67) | 53 (38-66) | 52 (36-68) | 54 (31-69) |
ECOG performance status, n (%) | Â | Â | Â | Â | Â | Â | Â | Â |
   0 | 60 (87.0) | 49 (74.2) | 21 (95.5) | 19 (95.0) | 21 (80.8) | 16 (61.5) | 18 (85.7) | 14 (70.0) |
   1 | 7 (10.1) | 15 (22.7) | 1 (4.5) | 1 (5.0) | 4 (15.4) | 9 (34.6) | 2 (9.5) | 5 (25.0) |
   2 | 2 (2.9) | 2 (3.1) | - | - | 1 (3.8) | 1 (3.8) | 1 (4.8) | 1 (5.0) |
ER or PgR positive, n (%) | 40 (58.0) | 38 (57.6) | 10 (45.5) | 7 (31.8) | 17 (65.4) | 19 (73.1) | 13 (61.9) | 12 (60.0) |
Previous epirubicin, n (%) | - | - | - | - | - | - | 21 (100) | 20 (100) |
   neoadjuvant |  |  |  |  |  |  | 3 (14.3) | 1 (5.0) |
   adjuvant |  |  |  |  |  |  | 18 (85.7) | 17 (85.0) |
   both |  |  |  |  |  |  | - | 2 (10.0) |
Dose of previous epirubicin, median (range), mg/m² | - | - | - | - | - | - | 422 (340-600) | 485 (289-779) |
At least one target lesion, n (%) | 53 (76.8) | 45 (68.2) | 22 (100) | 17 (77.3) | 20 (76.9) | 17 (65.4) | 11 (52.4) | 11 (55.0) |
Dominant site of disease, n (%) | Â | Â | Â | Â | Â | Â | Â | Â |
   soft tissues (chest wall, breast and nodes) | 31 (44.9) | 22 (33.3) | 22 (100) | 20 (100) | 6 (23.1) | 1 (3.8) | 3 (14.3) | 1 (5.0) |
   bone | 6 (8.7) | 4 (6.1) | - | - | 5 (19.2) | 2 (7.7) | 1 (4.8) | 2 (10.0) |
   viscera (including pleura) | 32 (46.4) | 40 (60.6) | - | - | 15 (57.7) | 23 (88.5) | 17 (81.0) | 17 (85.0) |